ArticleVirus research2026
IFNL3 reduces replication of CIRDC-associated viruses in canine airway epithelial cells.
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canine infectious respiratory disease complex (CIRDC) causes contagious respiratory disease in dogs and encompasses several etiologic agents. Viral pathogens associated with CIRDC include canine adenovirus type 2 (CAV-2), canine distemper virus (CDV), canine herpesvirus-1 (CaHV-1) and canine influenza virus (CIV). Vaccine availability and efficacy vary and there are currently no antivirals available for treatment. Interferons (IFNs) are at the frontline of the immune defense against many viral infections and interferon lambda (IFNL) has shown to be a potent antiviral. We hypothesized that canine interferon lambda-3 (IFNL3) treatment of canine respiratory epithelial cells (ALI-CRECs) will reduce replication of kennel cough viruses. ALI-CRECs were isolated, cultured and characterized morphologically and immunologically prior to infection with CDV, CaHV-1, CIV and CAV-2. The value of canine IFNL3 treatment for reducing viral titers as well as induction of interferon responses were evaluated for each virus. Treatment of ALI-CRECs with IFNL3 induced the expression of interferon stimulated genes. In addition, prophylactic IFNL3 administration resulted in a reduction in viral DNA with CT value changes of up to 13 intracellularly and up to 9 extracellularly. In contrast, for CDV and CaHV-1 a reduction in viral RNA/DNA was observed only intracellularly with CT value changes of up to 11 and up to 4 respectively. Prophylactic IFNL3 treatment also significantly reduced viral titers 1.2 to 3 log-fold for CAV-2, 0.9-2.5 log-fold for CDV, and 1.1-1.7 log-fold for CaHV-1. No effect of IFNL3 was observed for CIV RNA and CIV viral titers. Coinciding with a reduction in viral replication, interferon stimulated genes were differentially expressed in interferon treated and infected cells when compared with controls. In conclusion, ALI-CRECs have shown to be excellent systems to study respiratory viruses and evaluate the potential antiviral effect of IFNL3. However further in-depth mechanistic studies are needed to fully understand how IFNL3 stimulates/modulates local immune responses to induce antiviral effects. Moreover, while this study highlights the potential antiviral efficacy of IFNL3 for several canine respiratory viruses, determination of safety, effective doses in vivo as well as therapeutic potential will have to be evaluated in dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.